Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer

Sean Christopher Dowdy, Daniel S. Metzinger, John B. Gebhart, Preeti Srivatsa, Michael Haddock, Vera Jean Suman, Karl C. Podratz

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Our aim was to determine the outcomes associated with use of whole-abdominal radiation therapy (WART) in women with ovarian cancer, to identify predictors of response, and to assess associated toxicity. From 1981 through 2000, 171 women received WART at our institution after ovarian cancer surgery. Relevant clinical information was extracted through retrospective chart review. One hundred nine patients received WART after positive second-look laparotomy (SLL), and 62 were treated after secondary debulking (SD) for recurrent disease. The median dose to the whole abdomen was 25.5 Gy (range, 1.0-30.5 Gy). Therapy included a pelvic boost in 120 patients (70%) and a para-aortic boost in 21 patients (12%). The planned radiation course was completed in 123 patients (72%). In the SLL group, 5-year survival was 29% with a median follow-up of 98.4 months. The 5-year progression-free survival (PFS) was 41% in those with microscopic disease. There was one treatment-related death (1%). For the SD group, median PFS was 11 months and associated with treatment-related mortality in 5%. Overall, treatment-related small bowel obstruction occurred in 26 patients (15%). In patients with a positive SLL, WART should be considered only for those with microscopic residual disease. Treatment-related small bowel obstruction can be expected in 15% of these patients. Use of WART for recurrent disease appears to be related to serious bowel toxicity in 5% with an associated short disease-free interval; the therapeutic index of WART may not be acceptable in patients with recurrent disease regardless of the degree of cytoreduction.

Original languageEnglish (US)
Pages (from-to)389-394
Number of pages6
JournalGynecologic Oncology
Volume96
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Ovarian Neoplasms
Laparotomy
Radiotherapy
Disease-Free Survival
Therapeutics
Abdomen
Radiation
Survival
Mortality

Keywords

  • Cytoreduction
  • Laparotomy
  • Ovarian cancer
  • Whole-abdominal radiation therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer. / Dowdy, Sean Christopher; Metzinger, Daniel S.; Gebhart, John B.; Srivatsa, Preeti; Haddock, Michael; Suman, Vera Jean; Podratz, Karl C.

In: Gynecologic Oncology, Vol. 96, No. 2, 02.2005, p. 389-394.

Research output: Contribution to journalArticle

@article{aa58a7fbdc72427aa519245ddd0e3414,
title = "Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer",
abstract = "Our aim was to determine the outcomes associated with use of whole-abdominal radiation therapy (WART) in women with ovarian cancer, to identify predictors of response, and to assess associated toxicity. From 1981 through 2000, 171 women received WART at our institution after ovarian cancer surgery. Relevant clinical information was extracted through retrospective chart review. One hundred nine patients received WART after positive second-look laparotomy (SLL), and 62 were treated after secondary debulking (SD) for recurrent disease. The median dose to the whole abdomen was 25.5 Gy (range, 1.0-30.5 Gy). Therapy included a pelvic boost in 120 patients (70{\%}) and a para-aortic boost in 21 patients (12{\%}). The planned radiation course was completed in 123 patients (72{\%}). In the SLL group, 5-year survival was 29{\%} with a median follow-up of 98.4 months. The 5-year progression-free survival (PFS) was 41{\%} in those with microscopic disease. There was one treatment-related death (1{\%}). For the SD group, median PFS was 11 months and associated with treatment-related mortality in 5{\%}. Overall, treatment-related small bowel obstruction occurred in 26 patients (15{\%}). In patients with a positive SLL, WART should be considered only for those with microscopic residual disease. Treatment-related small bowel obstruction can be expected in 15{\%} of these patients. Use of WART for recurrent disease appears to be related to serious bowel toxicity in 5{\%} with an associated short disease-free interval; the therapeutic index of WART may not be acceptable in patients with recurrent disease regardless of the degree of cytoreduction.",
keywords = "Cytoreduction, Laparotomy, Ovarian cancer, Whole-abdominal radiation therapy",
author = "Dowdy, {Sean Christopher} and Metzinger, {Daniel S.} and Gebhart, {John B.} and Preeti Srivatsa and Michael Haddock and Suman, {Vera Jean} and Podratz, {Karl C.}",
year = "2005",
month = "2",
doi = "10.1016/j.ygyno.2004.10.007",
language = "English (US)",
volume = "96",
pages = "389--394",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer

AU - Dowdy, Sean Christopher

AU - Metzinger, Daniel S.

AU - Gebhart, John B.

AU - Srivatsa, Preeti

AU - Haddock, Michael

AU - Suman, Vera Jean

AU - Podratz, Karl C.

PY - 2005/2

Y1 - 2005/2

N2 - Our aim was to determine the outcomes associated with use of whole-abdominal radiation therapy (WART) in women with ovarian cancer, to identify predictors of response, and to assess associated toxicity. From 1981 through 2000, 171 women received WART at our institution after ovarian cancer surgery. Relevant clinical information was extracted through retrospective chart review. One hundred nine patients received WART after positive second-look laparotomy (SLL), and 62 were treated after secondary debulking (SD) for recurrent disease. The median dose to the whole abdomen was 25.5 Gy (range, 1.0-30.5 Gy). Therapy included a pelvic boost in 120 patients (70%) and a para-aortic boost in 21 patients (12%). The planned radiation course was completed in 123 patients (72%). In the SLL group, 5-year survival was 29% with a median follow-up of 98.4 months. The 5-year progression-free survival (PFS) was 41% in those with microscopic disease. There was one treatment-related death (1%). For the SD group, median PFS was 11 months and associated with treatment-related mortality in 5%. Overall, treatment-related small bowel obstruction occurred in 26 patients (15%). In patients with a positive SLL, WART should be considered only for those with microscopic residual disease. Treatment-related small bowel obstruction can be expected in 15% of these patients. Use of WART for recurrent disease appears to be related to serious bowel toxicity in 5% with an associated short disease-free interval; the therapeutic index of WART may not be acceptable in patients with recurrent disease regardless of the degree of cytoreduction.

AB - Our aim was to determine the outcomes associated with use of whole-abdominal radiation therapy (WART) in women with ovarian cancer, to identify predictors of response, and to assess associated toxicity. From 1981 through 2000, 171 women received WART at our institution after ovarian cancer surgery. Relevant clinical information was extracted through retrospective chart review. One hundred nine patients received WART after positive second-look laparotomy (SLL), and 62 were treated after secondary debulking (SD) for recurrent disease. The median dose to the whole abdomen was 25.5 Gy (range, 1.0-30.5 Gy). Therapy included a pelvic boost in 120 patients (70%) and a para-aortic boost in 21 patients (12%). The planned radiation course was completed in 123 patients (72%). In the SLL group, 5-year survival was 29% with a median follow-up of 98.4 months. The 5-year progression-free survival (PFS) was 41% in those with microscopic disease. There was one treatment-related death (1%). For the SD group, median PFS was 11 months and associated with treatment-related mortality in 5%. Overall, treatment-related small bowel obstruction occurred in 26 patients (15%). In patients with a positive SLL, WART should be considered only for those with microscopic residual disease. Treatment-related small bowel obstruction can be expected in 15% of these patients. Use of WART for recurrent disease appears to be related to serious bowel toxicity in 5% with an associated short disease-free interval; the therapeutic index of WART may not be acceptable in patients with recurrent disease regardless of the degree of cytoreduction.

KW - Cytoreduction

KW - Laparotomy

KW - Ovarian cancer

KW - Whole-abdominal radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=12344338192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344338192&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.10.007

DO - 10.1016/j.ygyno.2004.10.007

M3 - Article

C2 - 15661226

AN - SCOPUS:12344338192

VL - 96

SP - 389

EP - 394

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -